Fig. 3.
a, b Early immunotherapy in MO5 melanoma-bearing mice with VP1-OVA252-270 capsoids or VP1 PLPs in presence of OVA257-264 peptide. a Rate of tumour-free mice (in%) treated in each case twice with 50 μg of parental VP1 PLPs (filled triangle), VP1 PLPs plus 50 μg OVA257-264 peptide (filled inverted triangle) or VP1-OVA252-270 PLPs (filled diamond). The C57BL/6 mice were s.c. charged with 105 MO5 melanoma cells given into the right flank. The therapeutic immunisations or PBS administrations (filled square) were performed at day 4 and day 11 after s.c. melanoma implantation into the left flank. The animals were monitored for survival and tumour development for 60 days. b The survival rate of these treated mice was monitored daily (*P<0.05, log rank test, n=5). Mice that became moribund were sacrificed. Each experiment was repeated with similar results